MYCファミリーの腫瘍遺伝子の薬効性を解明する

Nishant M Karadkhelkar¹, Mingliang Lin¹, Lisa M Eubanks¹

¹Department of Chemistry, Department of Immunology and Microbial Science, The Skaggs Institute for Chemical Biology, and WIRM Institute for Research and Medicine, The Scripps Research Institute, La Jolla, California 92037, United States.

Journal of the American Chemical Society

|February 3, 2023

まとめ

MYC腫瘍遺伝子は細胞サイクル進行を調節することで癌を駆動する. 課題があるにもかかわらず MYC-MAX複合体を標的とした治療は多くのヒトの癌の治療戦略です

科学分野:

腫瘍学
分子生物学
生物化学

背景:

MYC家族 (MYC,MYCN,MYCL) は細胞サイクル進行の重要なレギュレータである.
MYCファミリーの遺伝子の放出は,すべてのヒトがんの半分以上の特徴であり,発症と維持に寄与します.
MYCの役割は,通常その直接的な病因と関連付けられていない癌に広がり,その広範な腫瘍学的影響を強調しています.

研究の目的:

MYCの生化学と,がんの進行状況におけるMAXとの相互作用をレビューする.
MYCは薬効性がないという考えに挑戦し,実現可能な治療戦略を探求する.
MYC- MAXをがん治療の標的とする可能性を議論する.

主な方法:

MYC-MAXヘテロディメリゼーションの生化学分析
MYCの腫瘍形成における役割に関する既存の文献のレビュー.
MYC-MAXを標的とした治療戦略の議論

主要な成果:

MYC- MAX複合体の形成は,がんに関与する多数の遺伝子の転写制御に不可欠です.
MYCの腫瘍性機能は変異ではなく過剰発現または増幅によって引き起こされる.
大きな相互作用面にもかかわらず,MYC-MAXをターゲットにすることは実現可能であり,治療の窓となる可能性があります.

結論:

MYCはヒトの様々な癌に重要な役割を果たす腫瘍発生因子です.
MYC- MAXの相互作用をターゲットにするという認識の難しさは,新たな治療法によって克服されています.
MYCを調節することでがん治療の有望な手段となり "薬効性のない"状態に挑戦できます

さらに関連する動画

08:18

Focus Formation: A Cell-based Assay to Determine the Oncogenic Potential of a Gene

Published on: December 31, 2014

28.1K

07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

209

関連する概念動画

01:06

Induced Pluripotent Stem Cells

4.2K

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...

4.2K

03:03

mTOR Signaling and Cancer Progression

3.8K

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

3.8K

02:23

Abnormal Proliferation

4.6K

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

4.6K

02:56

Treatment Resistant Cancers

3.4K

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

3.4K

01:25

Mutagenicity and Carcinogenicity

1.3K

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...

1.3K

02:38

Mitogens and the Cell Cycle

6.6K

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...